Lead: On August 21, 2026, the U.S. FDA once again made major news — it authorized 11 ZYN ULTRA series nicotine pouches from Swedish Match USA to be marketed. This brings the total number of legally marketed nicotine pouch products in the United States to 43, with the ZYN brand alone accounting for 31 of them. This is not merely a simple product expansion — it is another substantive endorsement by regulators of the harm-reduction potential of novel tobacco products.

01 Authorized Product List: 9 mg Dominates, New 11 mg Strength Added

The 11 newly authorized products all come from Swedish Match USA and are sold under the "ZYN ULTRA" brand. The full list is as follows:

表格

It is easy to see that the 9 mg strength is the absolute mainstay of this authorization, while the 11 mg Smooth flavor also successfully passed review, further expanding the strength gradient of the product line and offering adult users with different needs a broader range of choices.

02 The Landscape Behind the Numbers: 43 Products, ZYN Holds 31

As of August 21, 2026, the U.S. FDA has authorized a total of 43 nicotine pouch products for marketing in the U.S. Among them:

• ZYN brand: 31 products
• on! brand: 12 products

With a share of more than 72%, ZYN firmly holds the top spot among legally marketed nicotine pouch products. This is not only a reflection of market share — it also means that ZYN's product matrix has received the most extensive safety and harm-reduction certification at the regulatory level.

03 FDA's Review Logic: Not Just Labeled Strength, but "Actual Exposure"

In this review, the FDA made a key principle clear: nicotine exposure cannot be assessed solely by the milligrams printed on the packaging.

Factors affecting nicotine exposure include:

• Product design
• Formulation and manufacturing process
• Material characteristics
• Nicotine delivery rate

In other words, two products both labeled "9 mg" may deliver completely different actual nicotine exposure due to differences in formulation and process. The FDA reviewed each product individually based on its unique characteristics, incorporating them into an overall public health assessment.

04 Core Conclusions: Sufficient Evidence of Harm Reduction, Benefits Outweigh Risks

In this authorization announcement, the FDA reached several extremely critical conclusions:

First, significantly lower levels of harmful constituents. Compared with other oral and smokeless tobacco products, the authorized products contain lower levels of most harmful and potentially harmful constituents (HPHCs), with many constituents present at levels too low to quantify.

Second, sufficient nicotine delivery. The new products deliver adequate nicotine to users, thereby helping to a certain extent alleviate nicotine cravings and withdrawal symptoms. This means they genuinely possess the physiological basis to help traditional cigarette users "transition."

Third, population-level health benefits outweigh risks. The FDA explicitly determined that for adults aged 21 and older who use smokeless tobacco or cigarettes, completely switching to FDA-authorized nicotine pouches can reduce exposure to multiple harmful chemicals present in smokeless tobacco or cigarettes.

05 Not an Isolated Event: From PMTA to MRTP, the Regulatory Path Is Increasingly Clear

This authorization is not the first time the FDA has "given the green light" to nicotine pouch products. As early as January 2025, the FDA authorized 20 ZYN nicotine pouches for the first time. Then, in July 2026, the FDA went a step further, granting these 20 ZYN products Modified Risk Tobacco Product (MRTP) authorization — the highest level of harm-reduction certification under the U.S. tobacco regulatory framework.

This authorization allows Philip Morris International to explicitly state in marketing: "Using ZYN instead of cigarettes can reduce the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."

In 2026, the FDA also approved multiple on! brand nicotine pouch products in succession. The authorization of the ZYN ULTRA series marks that the entire nicotine pouch category has entered a phase of normalized, batch-by-batch authorization under the FDA's regulatory framework.

06 Final Thoughts: The Harm-Reduction Logic Is Being Embraced by Mainstream Regulation

In every authorization, the FDA has reiterated the same position: "This does not mean these products are safe" — but it has also repeatedly confirmed that for adult smokers who cannot or will not quit, completely transitioning from combustible tobacco to nicotine pouches can indeed effectively reduce health risks.

This is a subtle but clear signal: between "one-size-fits-all prohibition" and "complete inaction," science-based, risk-stratified regulation is becoming the consensus path for mainstream regulators around the world.

Of course, the FDA has also made clear that it will continue to monitor youth exposure to these products. The premise of harm reduction is always "targeting adult smokers" rather than "attracting the next generation."